drugset / Trial / NCT01340196

Drug Drug Interaction of BI 201335 and Tenofovir

NCT01340196

Phase 1 Completed 16 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the drug-drug interaction potential between BI 201335 and concomitantly administered tenofovir which is used in treatment regimens for HIV infection and/or Hepatitis B infection. Results of this study will serve as a basis for guidance of dose adjustments or other precautionary measures when BI201335 and tenofovir are coadministered.

Timeline

Start
2011-04
Primary completion
2011-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule
Subject Tenofovir Small molecule